On September 13, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that the Company and its researchers will present data from multiple studies using Guardant technology to advance precision oncology at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in Barcelona, Spain, September 13-17, 2024 (Press release, Guardant Health, SEP 13, 2024, View Source [SID1234646590]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data on the Guardant Reveal minimal residual disease test in patients with locally advanced rectal cancer enrolled in the NO-CUT trial will be presented in a presentation session at Presidential Symposium III. Additional presentations will focus on results from studies evaluating Guardant360 for treatment selection in advanced breast cancer and other solid tumors, as well as the Guardant Infinity response monitoring platform in advanced non-small cell lung cancer (NSCLC).
"Our latest data presented at ESMO (Free ESMO Whitepaper) further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types," said Dr. Craig Eagle, Chief Medical Officer at Guardant Health. "We look forward to demonstrating how Guardant’s tests can contribute to better outcomes across all stages of cancer care."
Full list of Guardant Health and collaborators’ presentations at ESMO (Free ESMO Whitepaper) 2024
Résumé
Title (translated from English) (Hall 6, unless otherwise indicated)
Product
Saturday, September 14 | 9:00 a.m. – 5:00 p.m.
1295P
EP0031, a next-generation selective RET inhibitor (SRI): correlation of molecular and clinical responses in patients with RET-positive solid tumors who are naïve or following prior SRI
Guardant Infinity
Sunday, September 15 | 9:00 a.m. – 5:00 p.m.
127P
Clinical utility of next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) to inform treatment decisions for patients with advanced solid tumors
360 guard
Monday, September 16 | 9:00 a.m. – 5:00 p.m.
418P
Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
360 guard
419P
Prevalence of gene rearrangement on NGS ctDNA and its targeting in patients with advanced breast cancer
360 guard
Monday, September 16 | 5:04 p.m. – 5:16 p.m.
509O
Total neoadjuvant therapy (TNT) with non-operative therapy (NOM) for effective mismatch repair of locally advanced rectal cancer (pMMR LARC): first results of the NO-CUT trial
Proposed communications session: Presidential Symposium III: Looking to the Future, Auditorium Barcelona, Hall 2
Saving Reveal
Full Guardant Health abstracts and a list of all abstracts presented at the ESMO (Free ESMO Whitepaper) Congress are available on the ESMO (Free ESMO Whitepaper) website .
Additional information and conference updates: Follow Guardant Health on LinkedIn , X (Twitter) and Facebook , or visit Guardant in person at booth #510.